Oxford, UK, February 2019 – Celleron Therapeutics, the UK-based company developing personalised medicines for cancer patients, on World Cancer Day affirms its commitment to start clinical trials in 2019 of new treatments for a variety of cancers
Celleron Therapeutics is a cancer drug development company based in the UK, which has close links to the University of Oxford.
World Cancer Day is an awareness event observed on 4th February 2019, led by the Union for International Cancer Control, a global consortium spanning over 120 countries. On World Cancer Day, www.worldcancerday.org the Celleron Therapeutics team recognise that every day is a struggle for those fighting cancer.
Professor Nick La Thangue, Founder and Chief Executive of Celleron Therapeutics, and Professor of Cancer Biology in the Department of Oncology at Oxford University, commented:
“Cancer remains a disease with huge impact and it is very important that we all recognise the importance of working together with common aims to develop effective therapies. Celleron is wholeheartedly committed to World Cancer Day.”
Celleron Therapeutics will register its clinical trials with the NHS National Institute for Health Research, which in 2018 was linked to 7,895 cancer research studies involving over 89,500 patients.
To additionally increase the access of our clinical trials to patients, Celleron Therapeutics has worked closely with the British science charity Cancer Research UK. Cancer Research UK has over 2000 trials on its ‘Find a Clinical Trial’ database. This is a complete resource for patients, health professionals and the research community, providing free information about studies which are open to patient enrolment, and summaries of results when available. Celleron have included details of its ongoing clinical trials with the anti-cancer drug CXD101 on this website https://www.cancerresearchuk.org/about-cancer/find-a-clinical-trial
Celleron Therapeutics’ focus is on those cancers where there is still an unmet need for long-term disease control. It is hoped that not only will patients volunteering in 2019 for our clinical trials benefit directly, but the results from these studies will ultimately allow the general use of more effective, safer medicines. Our goal is not only to treat cancer, but improve quality of life during therapy by reduction of side effects.
HOW IS CELLERON THERAPEUTICS MAKING A DIFFERENCE?
· Understanding the basic cell biology of cancer to pinpoint targets for new medicines
· Building a bridge between lab discovery and its translation into licensed medicines.
· Personalised therapy: Validating accompanying diagnostic tests which can then be used to select at a genetic level the best treatment for an individual.
· Bringing forward the next generation of treatments which help the body’s own immune defences to ‘seek and destroy’ cancers.
Celleron Therapeutics will not rest in this mission, this day and every day.
On World Cancer Day, each member of the team at Celleron Therapeutics says “I AM, I WILL”
Celleron Therapeutics is advancing a clinical and pre-clinical pipeline of precision therapies for different cancer indications. The company has built a proprietary platform around epigenetic control and immune modulation, providing its drugs with a two-pronged attack on cancer. Celleron’s approach seeks to align the right drug with the right patient enabling a personalised approach to cancer therapy. The company is a spin-out from Oxford University and located on the Oxford Science Park.
Celleron has a global license partnership with Astra Zeneca. The company secured investment in 2016 from a consortium of South Korean investors. For more information see www.cellerontherapeutics.com
To download this press release click here